Market Research Logo

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016’, provides in depth analysis on Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted pipeline therapeutics.

The report provides comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1)
  • The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) Overview
Therapeutics Development
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Products under Development by Stage of Development
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Products under Development by Therapy Area
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Products under Development by Indication
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Products under Development by Companies
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Companies Involved in Therapeutics Development
AdAlta Pty Ltd.
Bristol-Myers Squibb Company
Epigen Biosciences, Inc.
F. Hoffmann-La Roche Ltd.
Ono Pharmaceutical Co., Ltd.
RxBio, Inc.
Sanofi
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Drug Profiles
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITMN-10534 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rx-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-100842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Lysophosphatidic Acid Receptor 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Dormant Projects
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Featured News & Press Releases
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation
May 11, 2011: Amira To Present Preclinical Data On AM152 At Annual Meeting Of American Thoracic Society
May 02, 2011: Amira Pharmaceuticals Completes Phase I Clinical Study Of AM152
Apr 19, 2011: Amira Receives Orphan Drug Status For AM152 In Idiopathic Pulmonary Fibrosis
Oct 28, 2010: Amira Initiates Phase I Clinical Trial For AM152
Sep 27, 2010: Amira Submits AM152 IND To FDA For Potential Use In Fibrotic Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by AdAlta Pty Ltd., H1 2016
Pipeline by Bristol-Myers Squibb Company, H1 2016
Pipeline by Epigen Biosciences, Inc., H1 2016
Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Pipeline by RxBio, Inc., H1 2016
Pipeline by Sanofi, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report